CAR-T Therapy for Burkitt Lymphoma at Sheba Medical Center
O que está incluído neste pacote
Procedimentos médicos
- Terapia com células T CAR
- Exames de sangue
- Exame de sangue para bioquímica
- Biópsia
- Tomografia Computadorizada
- Consulta com um oncologista
- Consulta com um hematologista
- Consulta com um imunologista
- Consulta com um hematologista pediátrico
- Hemograma completo com marcadores tumorais e proteinograma
- Angiotomografia
- Eletrocardiograma (ECG)
- Exame de acompanhamento
- PET/TC
- Biomicroscopia ultrassónica (UBM)
- Consulta com um onco-hematologista
- Serviços de enfermagem 24 horas
- 3 refeições por dia pelo nutricionista
Duração
- 21 dias no hospital
Acomodação
Hospitalização
Transporte
Transfer aeroporto-clínica-aeroporto
Informações adicionais
CAR-T Therapy for Burkitt Lymphoma at Sheba Medical Center
For patients diagnosed with Burkitt Lymphoma, one of the most aggressive and fast-growing types of lymphoma, timing and access to advanced treatment are critical.
Sheba Medical Center, one of the world’s leading hospitals, offers advanced CAR-T cell therapy, providing new hope for patients with relapsed or treatment-resistant disease.
Sheba combines rapid treatment access, cutting-edge immunotherapy, and extensive clinical expertise to manage even the most challenging and fast-progressing cases.
A Faster Path to Life-Saving Treatment
At Sheba, the entire CAR-T process is performed on-site, ensuring speed, precision, and optimal cell quality essential for aggressive diseases like Burkitt Lymphoma.
• Apheresis – collection of the patient’s T-cells
• Cell Engineering – genetic modification at Sheba’s Advanced Biotherapy Center
• Infusion – reinfusion of modified cells designed to rapidly target and destroy lymphoma cells
By eliminating the need for external laboratories, treatment can begin in approximately 10 days, significantly reducing delays compared to many international centers.
CAR-T therapy acts as a “living therapy,” continuing to work in the body and offering the potential for rapid and durable remission.
All patients are treated under the leadership of Prof. Arnon Nagler, a globally recognized expert in hemato-oncology.
Advanced Treatment for Aggressive Disease
Burkitt Lymphoma requires immediate and highly specialized care. At Sheba, hematologists, oncologists, and immunotherapy experts work together to design a personalized treatment strategy, tailored to the urgency and biology of each case.
CAR-T therapy offers a powerful option for patients who have exhausted standard treatments, providing meaningful responses even in highly aggressive disease settings.
Why Patients Choose Sheba
• Rapid access to CAR-T therapy – treatment initiation in ~10 days
• Extensive experience – leading CAR-T program in the region
• Dedicated CAR-T units – with 24/7 expert monitoring
• Multidisciplinary expertise – integrated care across specialties
• Full international support – medical review, travel coordination, and patient assistance
Comprehensive, Personalized Care
Each patient undergoes a full diagnostic evaluation, including advanced imaging, bone marrow biopsy, genetic and molecular testing, and complete medical assessment, ensuring a precise and individualized treatment plan.
Services are provided in English, Russian, and Arabic, ensuring a smooth and supportive experience for international patients.
A Leading Center for Advanced Lymphoma Care
By combining speed, innovation, and world-class expertise, Sheba delivers one of the most advanced and accessible CAR-T programs for Burkitt Lymphoma worldwide offering patients a real chance for remission and improved survival in one of the most aggressive cancers.
Assistência Bookimed 24/7
- Coordenador médico pessoal
- Arranjos de viagem médica — reserva de passagens aéreas e quartos de hotel com preços especiais de parceiros
- Defesa do paciente durante a viagem médica
Preço do programa
O que NÃO está incluído neste pacote
Médico
Dr. Arnon Nagler is an internationally recognized hematologist and bone marrow transplant expert. He is a Professor of Medicine at Tel Aviv University. He is Director Emeritus of Hematology & Bone Marrow Transplantation and the Cord Blood Bank at Sheba Medical Center. He earned his M.D. from the Hebrew University–Hadassah and an M.Sc. in hematopoiesis from Tel Aviv University. He completed postdoctoral training at Stanford. He is board certified in internal medicine and hematology.
He has more than 35 years of experience. He pioneered reduced‑intensity allogeneic transplant protocols for malignant and non‑malignant diseases. He founded Israel’s first public cord blood bank. He performed the country’s first cord blood transplants.
He has held international leadership roles. He served as Chair and Co‑Chair of the ALWP of the EBMT. He was a vice‑chair and long‑term member of EBMT committees. He served on the board of NetCord/EuroCord and as treasurer. He is a frequent invited speaker. He has published widely in journals such as Blood and Leukemia. He has led major clinical trials as a principal investigator and held editorial roles. He has received multiple awards for innovation and clinical excellence.
Como estamos indo?
Sobre a clínica
A terapia com células CAR-T no Sheba Medical Center em Tel Aviv, Israel, pode custar cerca de US$ 63.100 pelo programa completo. O hospital está entre os 10 melhores do mundo e oferece este tratamento avançado sob a coordenação do Prof. Arnon Nagler, um renomado especialista em transplante de medula óssea.
Sobre o Tratamento
A terapia com células CAR-T é uma abordagem inovadora para leucemia, linfoma e mieloma múltiplo. O processo envolve a coleta das células T do paciente, sua modificação genética em laboratório e a reinfusão após a quimioterapia. O procedimento exige 21 dias de internação hospitalar, com possibilidade de permanência na UTI.
O que está incluído
- Avaliação abrangente (US$ 5.000 - US$ 10.000)
- Coleta de células via aférese (US$ 6.600)
- Preparação laboratorial das células modificadas (US$ 20.000)
- Quimioterapia de condicionamento (US$ 5.000)
- Internação de 21 dias (US$ 31.500)
- Avaliação pós-tratamento (US$ 3.000 - US$ 5.000)
Preparação e Recuperação
Os pacientes necessitam de biópsia de medula óssea, exames de PET/CT e exames de sangue antes do tratamento. Após a infusão, ocorre o monitoramento diário para a síndrome de liberação de citocinas. A permanência total recomendada em Israel é de 4 a 6 semanas. Vale ressaltar que o CAR-T para mieloma ainda é experimental.
O Sheba Medical Center atende 1,5 milhão de pacientes anualmente e oferece atendimento multilíngue. É necessário um depósito de US$ 50.000 a US$ 60.000 antes da chegada. Entre em contato com o hospital para avaliar se esta terapia é adequada para o seu caso.
Pagamento e Recompensas
Não pague por nossos serviços
Efetue o pagamento diretamente na clínica ou na conta bancária oficial dela.
Algumas clínicas podem exigir um depósito como parte de sua política.
Divida seus pagamentos com opções de parcelamento.
Ganhe recompensas por indicar amigos ao Bookimed.